Mounjaro: cost, evidence, and the honest comparison
Mounjaro is tirzepatide, the same dual-receptor molecule as Zepbound, labelled and studied for blood-sugar control in type 2 diabetes rather than for weight management.
What it's approved for
Type 2 diabetes — improving blood sugar alongside diet and exercise. Mounjaro is NOT approved for weight loss; Zepbound is the same molecule approved for that use.
Forms and doses: Once-weekly injection pen across the standard dose range.
What the research actually shows
Weight change is a well-documented effect in its diabetes trials, which is why the drug became famous beyond diabetes care. That does not make it an approved weight-loss product — the tirzepatide product approved for weight management is Zepbound.
Sources: FDA label information (DailyMed)
Side effects, stated plainly
Gastrointestinal effects dominate, as with the class, and the label carries the boxed warning regarding thyroid C-cell tumours in rodents. The label and your prescriber are the authority.
What it costs
The pricing gap is the whole story. LillyDirect self-pay lists Mounjaro at about $499 a month across all doses, against a list price near $1,023 — while the same molecule as Zepbound runs $299 to $449 by dose. If you are paying cash for tirzepatide, the route matters more than the molecule.
Keep reading
Common questions
Is Mounjaro on LillyDirect for cash pay?
Yes — LillyDirect lists self-pay Mounjaro at about $499 a month across dose strengths, roughly half of list price. The self-pay program is for people without commercial insurance, Medicare, or Medicaid coverage.
Why is Zepbound cheaper than Mounjaro if they are the same drug?
Same molecule, different label and different manufacturer program. Zepbound self-pay starts at $299 by dose; Mounjaro self-pay is a flat $499. For cash-paying weight-loss patients, Zepbound is both the approved product and the cheaper one.
Other weight loss medications
Wegovy · Zepbound · Foundayo · Ozempic · Compounded semaglutide · Compounded tirzepatide · Liraglutide
Mounjaro market news
The complaint targets sharing sensitive health data with ad platforms and ROSCA billing/cancellation practices — context for anyone weighing the $149/month membership model.
The Hims dossier →Participating Part D plans now cover Wegovy (pen and pill), Foundayo, and the Zepbound KwikPen at a flat $50 monthly copay through 2027 — below every cash price we track.
How the Bridge actually works →The proposed 503B Bulks List exclusion would close the mass-compounding era for good. Patient-specific 503A compounding continues — the legal market our index tracks at $139–$297 all-in.
The surviving market, explained →All tracked news → · Fed by a daily automated scan; entries publish only after primary-source verification.
Educational and pricing journalism, not medical advice — indications, dosing, and suitability are decisions for you and a licensed clinician, and the FDA label is the authority on risks. Prices carry the verification dates shown; the provider's checkout is the final word. Some links may earn commissions; rankings are ordered by cost, never compensation — disclosure.